Challenges in antibody titration for <scp>ABO</scp>‐incompatible renal transplantation

Kahlyar, Htar; Roxby, David; Badrick, Tony; Vanniasinkam, Thiru

doi:10.1111/vox.13160

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there was a wide variability in titre results between and within different technologies [16]. These findings demonstrate the need for an External Quality Assessment (EQA) program for ABO titration and the use of a standard technique that mayr educe the variability and enable to obtain equivalent results ( for IgM and IgG IHAs across centers, with a homogeneous clinical interpretation and better outcomes for patients [17].…”

Section: Approaches To Overcoming the Immunological Barrier Of The Ab...mentioning

confidence: 92%

Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation

Pierelli,

Matteocci

2024

Preprint

View full text Add to dashboard Cite

ABO incompatibility is not considered a contraindication for hematopoietic stem cell transplantation (HSCT). Approximately 30% of transplants from related donors and up to 50% of transplants from unrelated donors are ABO-incompatible. The immuno-hematologic investigationsmay evaluate donor/recipient ABO mismatch and anti-A/B isohemoagglutinins (IHAs) titration in pre-HSCT phase. Immediate hemolysis or delayed complications (passenger lymphocyte syndrome and pure red cell aplasia) can appear post-HSCT. Some preventive treatmentstake into consideration the manipulation of the product and decision-making algorithms based on the titration of IHAs in the recipient with clinical protocols for the removal/reduction of IHAs through plasma exchange or immunoadsorption procedures. Currently, the best approach in the managementof ABO-incompatibletransplant is not defined in expert consensus documents or with solid evidence. In addition, the methods for IHAs titration are not standardized. The transfusion strategy must consider both the blood group systems of the recipient and the donor until the RBC engraftment and the confirmed ABO conversion (forward and reverse typing) on two consecutive and independent samples. Therefore, ABO incompatibility in the HSCT is an important immuno-hematologic challenge and request all necessary preventive measures including the appropriate selection of ABO blood components for transfusion.

show abstract

Section: Approaches To Overcoming the Immunological Barrier Of The Ab...mentioning

confidence: 92%

Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation

Pierelli,

Matteocci

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…As a consequence, a wide variability in titer determination can be observed between and within different technologies [16]. These findings demonstrate the need for an External Quality Assessment (EQA) program for IHA titration and for the use of standard techniques that may reduce variability and enable the obtaining of comparable results across centers, with a more homogeneous clinical interpretation and better outcomes for patients [17].…”

Section: Approaches To Overcoming the Immunological Barrier Of The Ab...mentioning

confidence: 95%

Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation

Matteocci,

Pierelli

2024

Cells

View full text Add to dashboard Cite

ABO incompatibility is not considered a contraindication for hematopoietic stem cell transplantation (HSCT). Approximately 30% of transplants from related donors and up to 50% of transplants from unrelated donors are ABO incompatible. Immuno-hematologic investigations allow to estimate donor/recipient ABO mismatch and anti-A/B isohemagglutinin (IHA) titration in the pre-HSCT phase. Immediate hemolysis or delayed complications (passenger lymphocyte syndrome and pure red cell aplasia) can occur post HSCT. Some preventive measures take into consideration either decision-making algorithms based on the recipient’s IHA titration or clinical protocols for the removal/reduction of IHAs through plasma exchange or immunoadsorption procedures. Product manipulation through red blood cell (RBC) and/or plasma depletion can also be taken into account. Currently, the best approach in the management of ABO-incompatible transplant is not defined in expert consensus documents or with solid evidence. In addition, the methods for IHA titration are not standardized. A transfusion strategy must consider both the donor’s and recipient’s blood group systems until the RBC engraftment catches on and ABO conversion (forward and reverse typing) is confirmed on two consecutive and independent samples. Therefore, ABO incompatibility in HSCT represents a demanding immuno-hematologic challenge and requires all necessary preventive measures, including the appropriate selection of ABO blood components for transfusion.

show abstract

Advancement in preoperative desensitization therapy for ABO incompatible kidney transplantation recipients

Man

Gui

et al. 2023

Transplant Immunology

View full text Add to dashboard Cite

Challenges in antibody titration for ABO‐incompatible renal transplantation

Cited by 3 publications

References 28 publications

Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation

Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation

Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation

Advancement in preoperative desensitization therapy for ABO incompatible kidney transplantation recipients

Contact Info

Product

Resources

About